Last reviewed · How we verify
Hydroxypropyl Guar
At a glance
| Generic name | Hydroxypropyl Guar |
|---|---|
| Also known as | Control 1 |
| Sponsor | Universidad de Granada |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations (PHASE4)
- Effect of Treatment With Systane Ultra in Symptomatology and Visual Task Efficiency in Digital Device Users
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
- Fluoride Controlled-release System for Initial Lesions of Caries (PHASE2, PHASE3)
- Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV) (PHASE4)
- Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxypropyl Guar CI brief — competitive landscape report
- Hydroxypropyl Guar updates RSS · CI watch RSS
- Universidad de Granada portfolio CI